True to certain extent. The consensus in AD research community is that alteration of progression (slope change) is the key. That’s what is stressed in Biogen and Eisai trial as well. Overall, I think the impact of the changes is minimal in comparison with the changes in Avatar. All the data points must be released (such as Acadia did) to earn trust (unless Dr. M refuses). In the Avatar trial, if all the data are legit and transparent, Anavex2-73 would have been approved (or close to) everywhere. Few medications, if any, for developmental diseases have an effect size of 2 (Cohen’s D) with statistical significance. Well…..
Market Data 
Markets 
AI
